4 transcripts
URGN
Earnings call transcript
NASDAQ
2024 Q2
13 Aug 24
was primarily due to higher costs related to manufacturing of UGN-102 as well as R&D expenses in connection with our initiation of a Phase III study for UGN
URGN
Earnings call transcript
NASDAQ
2024 Q1
13 May 24
for UroGen that approved future R&D efforts, our corporate goals and 2024 financial guidance among other things.
These forward-looking statements
URGN
Earnings call transcript
NASDAQ
2023 Q4
14 Mar 24
of JELMYTO sales. R&D expenses were $11.3 million and $45.6 million, respectively, for the fourth quarter and full year 2023 compared with $14.5 million
URGN
Earnings call transcript
NASDAQ
2023 Q2
10 Aug 23
by higher R&D expense related to the Phase I study for UGN-301. Selling, general and administrative expenses for the second quarter 2023 were $22.5 million
- Prev
- 1
- Next